The inhibitory effect of rolipram on TNF-α production in mouse blood ex vivo is dependent upon the release of corticosterone and adrenaline

Cytokine

Volumn 9, Issue 8, 1997, Pages 582-586

  Pettipher, E Roy ^a   Eskra, James D ^a   Labasi, Jeffrey M ^a  

^a PFIZER INC   (United States)

Author keywords

cAMP phospodiesterase; Corticosterone; Leukocytes; TNF

Indexed keywords

ADRENALIN; CORTICOSTERONE; MIFEPRISTONE; PROPRANOLOL; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL FUNCTION; ADRENALECTOMY; ADRENALIN RELEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE RELEASE; DOSE RESPONSE; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ANIMALIA;

EID: 0031214686     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1997.0205     Document Type: Article

References (27)

1. 1. Arend WP, Dayer J-M (1995) Inhibition of the production and effects of interleukin 1 and tumor necrosis factor α in rheumatoid arthritis. Arthr Rheum 38:151-160.
2. 2. Saklatvala J (1986) Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547-549.
3. 3. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann (1989) Inhibitory effect of TNF-α antibodies on synovial cell interleukin 1 production in rheumatoid arthritis. Lancet ii:244-247.
4. 4. Haworth C, Brennan FM, Chantry D, Turner M, Maini R, Feldmann M (1991) Expression of granulocyte-macrophage colony stimulating factor (GM-CSF) in rheumatoid arthritis: regulation by tumour necrosis factor-α. Eur J Immunol 21:2575-2579.
5. 5. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthr Rheum 36:1681-1690.
6. 6. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110.
7. 7. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34:334-342.
8. 8. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561.
9. 9. Wooley PH, Dutcher J, Widmer MB, Gillis S (1993) Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602-6607.
10. 10. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, Piguet PF, Pointaire P, Vassalli P, Loetscher H (1991) Recombinant soluble tumor necrosis factor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 21: 2883-2886.
11. 11. Williams RO, Ghrayeb J, Feldmann M, Maini RN (1995) Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84:433-439.
12. 12. Semmler J, Wachtel H, Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 15:409-413.
13. 13. Turner C, Esser KM, Wheeldon EB (1993) Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Circ Shock 39:237-245.
14. 14. Badger AM, Olivera DL, Esser KM (1994) Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline and rolipram in a murine model of endotoxin shock. Circ Shock 44:188-195.
15. 15. Sekut L, Yarnall D, Stimpson SA, Noel LS, Bateman-Fite R, Clark RL, Brackeen MF, Menius JA, Connolly KM (1995) Antiinflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 100:126-132.
16. 16. Pettipher ER, Labasi JM, Salter ED, Stam EJ, Cheng JB, Griffiths RJ (1996) Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram. Br J Pharmacol 117:1530-1534.
17. 17. Desch CE, Kovach NL, Present W, Broyles C, Harlan JM (1989) Production of human tumor necrosis factor from whole blood ex vivo. Lymphokine Res 8:141-146.
18. 18. Stricter RM, Remick DG, Ham JM, Colletti LM, Lynch JP, Kunkel SL (1990) Tumor necrosis factor-alpha gene expression in human blood. J Leukocyte Biol 47:366-370.
19. 19. Hadley AJ, Flack JD, Buckingham JC (1991) Potentiation of cyclic AMP mediated corticotrophin (ACTH) release by denbufylline in vivo and in vitro. Br J Pharmacol 104:313P.
20. 20. Klemm P, Harris HJ, Perretti M (1995) Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Eur J Pharmacol 281:69-74.
21. 21. Kvetnansky R, Sun CL, Lake CR, Thoa N, Torda T, Kopin IJ (1978) Effect of handling and forced immobilization on rat plasma levels of epinephrine, norepinephrine and dopamine-β-hydroxylase. Endocrinology 103:1868-1874.
22. 22. Severn A, Rapson NT, Hunter CA, Liew FY (1992) Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J Immunol 148:3441-3445.
23. 23. Brissette WH, Baker DA, Stam EJ, Umland JP, Griffiths RJ (1995) GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF. Cytokine 7:291-295.
24. 24. Pettipher ER, Salter ED (1996) Resident joint tissues, rather than infiltrating neutrophils and monocytes, are the predominant sources of TNF-α in zymosan-induced arthritis. Cytokine 8:130-133.
25. 25. Higbee MD, Kumar M, Galant SP (1982) Stimulation of endogenous catecholamine release by theophylline: a proposed additional mechanism of action for theophylline effects. J Allergy Clin Immunol 70:377-382.
26. 26. Vestal RE, Eiriksson CE, Musser B, Ozaki LK, Halter JB (1983) Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man. Circulation 67:162-171.
27. 27. Candito M, Albertini M, Politano S, Deville A, Mariani R, Chambon P (1993) Plasma catecholamine levels in children. J Chromatogr 617:304-307.